ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer-Reference-Cited by-同舟云学术

ACCENT-Based Web Calculators to Predict Recurrence and Overall Survival in Stage III Colon Cancer

Published:2014-10-29 Issue:12 Volume:106 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Renfro Lindsay A.,Grothey Axel,Xue Yuan,Saltz Leonard B.,André Thierry,Twelves Chris,Labianca Roberto,Allegra Carmen J.,Alberts Steven R.,Loprinzi Charles L.,Yothers Greg,Sargent Daniel J.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/106/12/dju333/17313664/dju333.pdf

Reference24 articles.

1. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer;André;N Engl J Med,2004

2. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial;André;J Clin Oncol,2009

3. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients;Schmoll;J Clin Oncol,2006

4. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses;Yothers;J Clin Oncol,2011

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials;Journal of Clinical Oncology;2024-07-01

2. Multivariable prognostic modelling to improve prediction of colorectal cancer recurrence: the PROSPeCT trial;European Radiology;2024-06-05

3. Machine learning for predicting colon cancer recurrence;Surgical Oncology;2024-06

4. Post‐diagnosis adiposity and colorectal cancer prognosis: A Global Cancer Update Programme (CUP Global) systematic literature review and meta‐analysis;International Journal of Cancer;2024-05

5. Integration of pathologic characteristics, genetic risk and lifestyle exposure for colorectal cancer survival assessment;Nature Communications;2024-04-08